The phase II Tasigna Efficacy in Advanced Melanoma trial suggested that nilotinib, a KIT-selective tyrosine kinase inhibitor, may be an effective therapy option for individuals with KIT-mutated advanced melanoma (59). The gene discussed is KIT; the disease is melanoma.